Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
28.22
-0.49 (-1.71%)
At close: Apr 28, 2026, 4:00 PM EDT
28.13
-0.09 (-0.32%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Pharvaris Employees
Pharvaris had 129 employees as of December 31, 2025. The number of employees increased by 21 or 19.44% compared to the previous year.
Employees
129
Change (1Y)
21
Growth (1Y)
19.44%
Revenue / Employee
n/a
Profits / Employee
-$1,599,167
Market Cap
1.85B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Galapagos NV | 558 |
| Vericel | 398 |
| Syndax Pharmaceuticals | 298 |
| Harmony Biosciences Holdings | 293 |
| Stoke Therapeutics | 170 |
| Inhibrx Biosciences | 110 |
| AnaptysBio | 104 |
PHVS News
- 8 days ago - Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference - GlobeNewsWire
- 26 days ago - Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology - GlobeNewsWire
- 6 weeks ago - Pharvaris Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology - GlobeNewsWire
- 7 weeks ago - Pharvaris Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 2 months ago - Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 - GlobeNewsWire
- 2 months ago - Pharvaris Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts